GASTRIC ADENOCARCINOMA

This study tested two experimental drugs (AK104 and AK117) together, sometimes with chemotherapy, in 128 people with advanced solid tumors. The goal was to see if the combination is safe and can shrink tumors. It focused on patients with stomach, esophageal, or other advanced can…

This phase 2 trial tested personalized immunotherapy combinations for advanced gastric cancer that had worsened after initial chemotherapy. Researchers matched treatments to tumor genetics: patients with certain genetic features received atezolizumab plus ipatasertib, while other…

This early-phase trial tested two drugs together—pembrolizumab (Keytruda) and XL888—in 47 people with advanced gastrointestinal cancers like colorectal and pancreatic cancer that had spread or could not be removed. The main goal was to find the safest dose and check for side effe…

This study tested a mix of three drugs—trastuzumab deruxtecan (a targeted therapy), nivolumab (an immunotherapy), and chemotherapy—in 30 people with untreated HER2-low stomach or gastroesophageal junction cancer. The goal was to first find a safe dose and then see how well it shr…

This early-phase trial tested a combination of two targeted drugs (regorafenib and nivolumab) plus standard chemotherapy in 30 adults with advanced or recurrent stomach, gastroesophageal junction, or esophageal adenocarcinoma that could not be surgically removed. The goal was to …

This completed Phase 2 trial tested whether a special DNA-based test could predict how well patients with stomach or rectal cancer respond to immunotherapy (tislelizumab) combined with chemotherapy and/or radiation. 189 adults with advanced cancer participated. The goal was to se…

This completed Phase 2 study tested a combination of chemotherapy (FOLFIRI) and radiation with 5-fluorouracil in 63 patients with gastric cancer. The treatment was given either before or after surgery to remove the tumor. The goal was to see if this approach is feasible and less …

This early-stage study tested a new drug called cabotamig in 33 adults with advanced cancers of the digestive system (like colon, pancreas, or liver) that had stopped responding to standard treatments. The goal was to see if the drug is safe and how it affects the body and tumors…

This phase 3 trial tested whether adding the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy before and after surgery helps people with stomach or gastroesophageal junction cancer. Over 1,000 participants received either pembrolizumab plus chemo or placebo pl…

This study tested whether adding the drug pembrolizumab to standard chemotherapy helps Chinese adults with stomach or gastroesophageal junction cancer. Participants received the drug combination or a placebo before and after surgery. The goal was to see if the combination improve…

This study tested a combination of two experimental drugs, AK112 and AK117, with or without chemotherapy, in 154 people with advanced solid tumors. The goal was to see if the combo could shrink tumors and control the disease. The trial has finished, and researchers are now lookin…

This phase 2 study tested a combination of two drugs, TAS 102 (Lonsurf) and ramucirumab (Cyramza), in 23 patients with advanced stomach or gastroesophageal junction cancer that had stopped responding to other treatments. The goal was to see if the combo was safe and could help pa…

This study compared two types of surgery for stomach cancer: laparoscopic (keyhole) and open surgery. The goal was to see if keyhole surgery leads to a shorter hospital stay and fewer complications. The trial included 210 patients with resectable stomach cancer and is now complet…

This study tested a new immunotherapy drug, ezabenlimab, combined with other cancer medicines in 211 adults with advanced solid tumors that had spread. The goal was to see if the tumors shrank or disappeared. Participants received different drug combinations, and doctors monitore…

This early-phase trial tested a combination of two drugs—pembrolizumab (an immunotherapy) and nintedanib (a drug that blocks blood vessel growth)—in 196 adults with advanced solid tumors that had worsened after standard treatment. The main goal was to find the safest dose of nint…

This study tested an experimental drug called RC88 in 198 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors or slow their growth. The study was completed and looked at sid…

This early-stage trial tested the safety of a new drug called SGN-B6A in 6 Chinese patients with advanced solid tumors (lung, head and neck, esophageal, stomach cancers). The main goal was to identify side effects and see how the body processes the drug. It is a first step to see…

This study tested several immunotherapy-based drug combinations in 214 people with advanced stomach, gastroesophageal junction, or esophageal cancer that could not be removed by surgery or had spread. Participants received either standard chemotherapy or chemotherapy plus the imm…

This study tested a new treatment combination (GEN-001 plus avelumab) in 42 people with advanced stomach or gastroesophageal junction cancer that had not responded to at least two prior therapies. All participants had a specific marker (PD-L1 positive) on their tumors. The goal w…

This study tested a new drug (TJ004309) combined with an approved immunotherapy (atezolizumab) in 25 people with advanced ovarian, head and neck, lung, gastrointestinal, or triple-negative breast cancers. The goal was to see if the combination could shrink tumors. Participants ha…

This phase 3 trial tested whether adding an immunotherapy drug called AK104 to standard chemotherapy helps people with advanced stomach or gastroesophageal junction cancer live longer. About 610 participants received either AK104 plus chemo or a placebo plus chemo. The study is c…

This early-phase trial tested a combination of three drugs—afuresertib, sintilimab, and chemotherapy—in 22 adults with solid tumors (including lung, cervical, and stomach cancers) that had stopped responding to prior immunotherapy. The goal was to find a safe dose and see if the …

This study tested a combination of an oral bacterial product (VE800) and the immunotherapy drug nivolumab in 56 people with advanced or metastatic cancers like melanoma, stomach, and colorectal cancer. The goal was to see if the bacteria could help the immune system fight tumors …

This Phase 3 trial tested whether adding the immunotherapy drug camrelizumab to standard chemotherapy, followed by camrelizumab plus the targeted drug apatinib, helps people with advanced stomach or gastroesophageal junction cancer live longer. The study enrolled 885 participants…

This early-phase study tested an experimental drug called TPST-1495, taken as a pill, either alone or combined with the immunotherapy Keytruda (pembrolizumab). The trial included 89 people with advanced solid tumors like colorectal, lung, head and neck, and endometrial cancers wh…

This trial compares two minimally invasive surgical techniques for removing the lower part of the stomach in people with gastric cancer: laparoscopy-assisted distal gastrectomy (LADG) and totally laparoscopic distal gastrectomy (TLDG). The goal is to see which approach leads to b…

This phase II trial tested a concentrated plant dietary supplement (made from foods like taro, rice, and carrots) in 30 people with gastrointestinal cancers who had diarrhea from chemotherapy. Participants received the supplement alongside standard anti-diarrheal treatment. The g…

This study looks at whether a 4-week pre-surgery program of exercise, nutrition advice, and mental support, combined with a standard enhanced recovery plan, can reduce complications after stomach cancer surgery. About 136 patients aged 18-75 who had chemotherapy before surgery wi…

This study created a new tool called the SAH Index to fairly evaluate how well hospitals and surgeons perform gastric cancer surgery. Gastric cancer is serious and often requires major surgery, but comparing results is tricky because patients have different health risks. The rese…

This study looked at whether an AI computer program could suggest cancer treatments that match what experts recommend. Researchers reviewed medical records of 30 people with stomach, colon, or pancreatic cancer. They entered key details into the AI and compared its suggestions to…

This completed study looked at 51 adults with stomach cancer in Portugal to see how many carry inherited gene changes linked to the disease. Researchers used a multigene panel test to check for these mutations. The goal was to understand how common these genetic factors are in th…

This study looked at 258 adults with untreated oeso-gastric cancer to understand how factors like income, education, and personal beliefs affect the time between first noticing symptoms and seeing a doctor. Researchers measured the median delay from symptom onset to first consult…

This study looked at whether two easy-to-use frailty checklists (FRAIL and FiND) can predict severe side effects from chemotherapy in adults aged 65 and older with gastrointestinal cancers. Researchers followed 84 patients who had already had surgery and were receiving standard c…

This completed study from Fudan University used a deep learning model to predict whether stomach cancer will come back after surgery. Researchers analyzed data from 5,000 patients across multiple hospitals in Eastern Asia. The model showed strong ability to identify early recurre…

This study looked back at 96 patients with advanced stomach cancer who had either partial or total stomach removal. Researchers compared survival rates and recovery to see which surgery might be better. The goal is to help doctors and patients choose the best surgical approach.

This study looked at over 8,500 people with stomach cancer in Brandenburg, Germany, from 2000 to 2020. Researchers wanted to understand how the disease and survival differ between men and women. They used cancer registry data to analyze these differences, without giving any new t…

This study tested a risk scoring model that predicts whether stomach cancer has spread to nearby lymph nodes before surgery. Researchers looked at data from 120 patients who had their stomach cancer removed. The goal was to see if the model could help doctors make better treatmen…